HY-004 provides a new treatment alternative for use in patients on anti-coagulant therapies undergoing dental procedures that have a risk of bleeding or complication HY-004 administered locally had ...
* Board declared an interim dividend of HK2.5 cents per share for six months ended 30 June 2017 * Group's revenue in six months ended 30 June 2017 was approximately HK$1.08 billion, up 39.7 pct * HY ...
Hyloris Pharmaceuticals SA, a specialty biopharma company, announced positive results from a phase 1 study of HY-004, an antifibrinolytic agent, tranexamic acid, as an oral mouth rinse proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results